Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
iBio Inc has a consensus price target of $2.92 based on the ratings of 4 analysts. The high is $5 issued by Chardan Capital on June 3, 2024. The low is $0.17 issued by Cantor Fitzgerald on October 7, 2022. The 3 most-recent analyst ratings were released by Brookline Capital, Chardan Capital, and Chardan Capital on July 22, 2024, June 3, 2024, and May 28, 2024, respectively. With an average price target of $4.53 between Brookline Capital, Chardan Capital, and Chardan Capital, there's an implied 107.00% upside for iBio Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for iBio (AMEX:IBIO) was reported by Brookline Capital on July 22, 2024. The analyst firm set a price target for $3.60 expecting IBIO to rise to within 12 months (a possible 64.38% upside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for iBio (AMEX:IBIO) was provided by Brookline Capital, and iBio initiated their buy rating.
There is no last upgrade for iBio
The last downgrade for iBio Inc happened on February 16, 2023 when JMP Securities changed their price target from N/A to N/A for iBio Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of iBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for iBio was filed on July 22, 2024 so you should expect the next rating to be made available sometime around July 22, 2025.
While ratings are subjective and will change, the latest iBio (IBIO) rating was a initiated with a price target of $0.00 to $3.60. The current price iBio (IBIO) is trading at is $2.19, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.